HENLIUS Surges Over 8% on Pakistan Approval and Inclusion in National Essential Drug List

Stock News09-21

HENLIUS (02696) saw its shares jump more than 8% in morning trading, with the stock last changing hands at HK$64.80, representing an 8.56% gain, and turnover reaching HK$20.10 million.

On the news front, the company recently announced, via its official WeChat account, that its commercial partner Getz Pharma (Private) Limited ("Getz Pharma") has received the relevant registration certificate. This confirms that HENLIUS's self-developed and manufactured product, Han Dayuan (adalimumab), has been granted marketing approval by the Drug Regulatory Authority of Pakistan (DRAP), with the trade name Adaliget. The approval covers all indications that the originator adalimumab holds in the local market.

With this approval, Han Dayuan becomes the company's eighth product to receive overseas marketing authorization, following other products such as Han Qu You (trastuzumab, tradenames Zercepac in Europe and HERCESSI in the US), H drug Hans Zhuang (serplulimab, tradename Hetronifly in Europe), Han Bei You (pertuzumab, tradename Poherdy in Europe and the US), and Han Bei Tai (bevacizumab).

Additionally, Han Dayuan was included in the National Essential Drug List (2026 Edition) of China in July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117397705?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-21 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117397705","market":"sg","top_or_hot":-1,"title":"HENLIUS Surges Over 8% on Pakistan Approval and Inclusion in National Essential Drug List","media":"Stock News","content":"<p><b>HENLIUS</b> (02696) saw its shares jump more than 8% in morning trading, with the stock last changing hands at HK$64.80, representing an 8.56% gain, and turnover reaching HK$20.10 million.<br><br>On the news front, the company recently announced, via its official WeChat account, that its commercial partner Getz Pharma (Private) Limited (\"Getz Pharma\") has received the relevant registration certificate. This confirms that <b>HENLIUS</b>'s self-developed and manufactured product, Han Dayuan (adalimumab), has been granted marketing approval by the Drug Regulatory Authority of Pakistan (DRAP), with the trade name Adaliget. The approval covers all indications that the originator adalimumab holds in the local market.<br><br>With this approval, Han Dayuan becomes the company's eighth product to receive overseas marketing authorization, following other products such as Han Qu You (trastuzumab, tradenames Zercepac in Europe and HERCESSI in the US), H drug Hans Zhuang (serplulimab, tradename Hetronifly in Europe), Han Bei You (pertuzumab, tradename Poherdy in Europe and the US), and Han Bei Tai (bevacizumab).<br><br>Additionally, Han Dayuan was included in the National Essential Drug List (2026 Edition) of China in July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS Surges Over 8% on Pakistan Approval and Inclusion in National Essential Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS Surges Over 8% on Pakistan Approval and Inclusion in National Essential Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-21 09:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>HENLIUS</b> (02696) saw its shares jump more than 8% in morning trading, with the stock last changing hands at HK$64.80, representing an 8.56% gain, and turnover reaching HK$20.10 million.<br><br>On the news front, the company recently announced, via its official WeChat account, that its commercial partner Getz Pharma (Private) Limited (\"Getz Pharma\") has received the relevant registration certificate. This confirms that <b>HENLIUS</b>'s self-developed and manufactured product, Han Dayuan (adalimumab), has been granted marketing approval by the Drug Regulatory Authority of Pakistan (DRAP), with the trade name Adaliget. The approval covers all indications that the originator adalimumab holds in the local market.<br><br>With this approval, Han Dayuan becomes the company's eighth product to receive overseas marketing authorization, following other products such as Han Qu You (trastuzumab, tradenames Zercepac in Europe and HERCESSI in the US), H drug Hans Zhuang (serplulimab, tradename Hetronifly in Europe), Han Bei You (pertuzumab, tradename Poherdy in Europe and the US), and Han Bei Tai (bevacizumab).<br><br>Additionally, Han Dayuan was included in the National Essential Drug List (2026 Edition) of China in July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000165453.HKD","symbol_name":"华夏精选大中华科技基金 A类港币","start_time":0,"source_url":"","article_id":"1117397705","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117397705","pubTimestamp":1789955899,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) saw its shares jump more than 8% in morning trading, with the stock last changing hands at HK$64.80, representing an 8.56% gain, and turnover reaching HK$20.10 million.On the news...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","02696":"复宏汉霖","BK4585":"ETF&股票定投概念","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK1161":"生物科技","KCAI":"KraneShares China Alpha Index ETF","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC"},"translate_title":"复宏汉霖在巴基斯坦获批并被纳入国家基本药物目录后飙升超过 8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02696":1,"KCAI":1},"content_text":"HENLIUS (02696) saw its shares jump more than 8% in morning trading, with the stock last changing hands at HK$64.80, representing an 8.56% gain, and turnover reaching HK$20.10 million.On the news front, the company recently announced, via its official WeChat account, that its commercial partner Getz Pharma (Private) Limited (\"Getz Pharma\") has received the relevant registration certificate. This confirms that HENLIUS's self-developed and manufactured product, Han Dayuan (adalimumab), has been granted marketing approval by the Drug Regulatory Authority of Pakistan (DRAP), with the trade name Adaliget. The approval covers all indications that the originator adalimumab holds in the local market.With this approval, Han Dayuan becomes the company's eighth product to receive overseas marketing authorization, following other products such as Han Qu You (trastuzumab, tradenames Zercepac in Europe and HERCESSI in the US), H drug Hans Zhuang (serplulimab, tradename Hetronifly in Europe), Han Bei You (pertuzumab, tradename Poherdy in Europe and the US), and Han Bei Tai (bevacizumab).Additionally, Han Dayuan was included in the National Essential Drug List (2026 Edition) of China in July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117397705","isCrawlerRequest":true}